ConvaTec Group (LON:CTEC) Insider Purchases £113,000 in Stock
by Kim Johansen · The Markets DailyConvaTec Group PLC (LON:CTEC – Get Free Report) insider Tobias Hestler acquired 50,000 shares of the stock in a transaction on Thursday, August 6th. The shares were acquired at an average cost of GBX 226 per share, for a total transaction of £113,000.
ConvaTec Group Trading Up 2.5%
LON CTEC opened at GBX 232.40 on Monday. The firm’s fifty day moving average is GBX 213.38 and its two-hundred day moving average is GBX 220.96. ConvaTec Group PLC has a one year low of GBX 193 and a one year high of GBX 259.30. The company has a debt-to-equity ratio of 121.83, a quick ratio of 0.96 and a current ratio of 1.93. The firm has a market cap of £4.54 billion, a PE ratio of 27.02, a P/E/G ratio of 0.93 and a beta of 0.77.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently commented on CTEC shares. Citigroup cut their price target on ConvaTec Group from GBX 250 to GBX 230 and set a “neutral” rating for the company in a research note on Monday, May 18th. Peel Hunt reissued an “add” rating and issued a GBX 270 price objective on shares of ConvaTec Group in a research note on Tuesday, August 4th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a GBX 315 price objective on shares of ConvaTec Group in a research report on Wednesday, August 5th. Berenberg Bank restated a “buy” rating and issued a GBX 340 target price on shares of ConvaTec Group in a research note on Tuesday, April 21st. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a GBX 315 target price on shares of ConvaTec Group in a report on Monday, August 3rd. Eight analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of GBX 306.
Check Out Our Latest Analysis on CTEC
About ConvaTec Group
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.